Novo Nordisk's Denecimig Achieves 99% Reduction in Bleeding Episodes for Hemophilia A Patients in Phase 3 Trial
核心洞察
Novo Nordisk's investigational denecimig demonstrated remarkable efficacy in the phase 3 FRONTIER2 trial, reducing bleeding episodes by up to 99% compared to on-demand treatment and 43-54% versus prior prophylaxis in hemophilia A (搜索) patients.
The bispecific antibody showed consistent benefits across 254 adults and adolescents regardless of inhibitor status, with 64-95% of participants experiencing zero treated bleeds during the 26-week study period.
Published in the New England Journal of Medicine, these results support denecimig's potential as a once-monthly or once-weekly prophylactic treatment, with the drug currently under FDA review following BLA submission in September 2025.
Novo Nordisk's investigational hemophilia A (搜索) treatment denecimig has demonstrated unprecedented efficacy in reducing bleeding episodes, according to pivotal phase 3 results published in the New England Journal of Medicine. The FRONTIER2 trial showed that the bispecific antibody reduced annualized bleeding rates by up to 99% compared to on-demand treatment and by 43-54% versus prior clotting factor prophylaxis in adults and adolescents with hemophilia A.
Breakthrough Efficacy Results
The 26-week FRONTIER2 study evaluated 254 participants aged 12 years and older with hemophilia A (搜索), both with and without Factor VIII (搜索) inhibitors. Patients receiving once-monthly denecimig experienced nearly 99% fewer bleeding episodes compared to on-demand treatment and approximately 43% fewer bleeds than their previous preventive clotting factor therapy. Those on once-weekly dosing saw approximately 96% fewer bleeds versus on-demand treatment and about 54% fewer bleeds compared to prior prophylaxis.
"The prevention and reduction of bleeding episodes is the ultimate goal for people living with hemophilia A (搜索)," said Dr. Maria Elisa Mancuso, Senior Consultant in Hematology at the Center for Thrombosis and Haemorrhagic Diseases, IRCCS Humanitas Research Hospital in Milan, Italy and lead investigator of the trial. "These results from the FRONTIER2 study provide important data on the potential of denecimig as a preventive treatment option regardless of hemophilia A severity or inhibitor status."
Remarkable Zero-Bleed Rates
The study revealed striking differences in participants achieving zero treated bleeding episodes. Among the four denecimig treatment arms, 64-95% of participants reported zero treated bleeds, depending on the specific arm. In contrast, comparator arms showed zero treated bleeds in only 0-37% of participants, with 0% in the on-demand arm, 33% in the pre-study clotting factor prophylaxis arm transitioning to once-weekly denecimig, and 37% in the pre-study prophylaxis arm moving to once-monthly denecimig.
Study Population and Design
Of the 254 enrolled patients, 246 completed the 26-week main phase. The study population included four females (2%), 66 adolescents aged 12-17 years (26%), 212 patients with severe hemophilia A (搜索) (84%), and 31 patients with FVIII inhibitors (12%). The trial's primary endpoint was the mean annualized bleeding rate of treated bleeds.
Safety Profile
Denecimig demonstrated a favorable safety profile throughout the study period. No thromboembolic events or clinical evidence of neutralizing anti-denecimig antibodies were reported. Injection-site reactions occurred in 10% of participants, with reactions observed in 2.6% of total injections administered.
Mechanism of Action and Regulatory Status
Denecimig is an investigational Factor VIIIa (搜索) mimetic bispecific antibody administered subcutaneously. The drug mimics Factor VIIIa function by bridging Factor IXa (搜索) and Factor X, helping restore the body's thrombin generation capacity and enabling proper blood clotting. This mechanism allows it to work effectively in patients both with and without Factor VIII (搜索) inhibitors.
"With denecimig recently submitted to the FDA through a Biologics License Application, these NEJM data further underscore its potential as a preventive treatment option that may help address the persistent unmet needs of people living with hemophilia A (搜索), with or without inhibitors," said Anna Windle, PhD, Head of Clinical Development, Medical & Regulatory Affairs at Novo Nordisk US Operations.
Novo Nordisk submitted denecimig for FDA review through a Biologics License Application in September 2025, marking a significant regulatory milestone for the investigational treatment.
Addressing Unmet Medical Need
Hemophilia A (搜索) affects approximately 836,000 people worldwide according to the World Federation of Hemophilia, representing 80-85% of all hemophilia cases. The condition is caused by missing or defective clotting Factor VIII (搜索), and approximately 30% of patients develop inhibitors that can render standard replacement therapy ineffective.
The FRONTIER2 results represent part of Novo Nordisk's broader FRONTIER program, which includes studies FRONTIER1-5 investigating denecimig across pediatric and adult populations with hemophilia A (搜索). The comprehensive program aims to establish denecimig as a preventive treatment option with flexible dosing frequencies ranging from once-weekly to once-monthly administration.